US008314077B2 (12) United States Patent (10) Patent No.: US 8,314,077 B2 Webb et al. (45) Date of Patent: *Nov. 20, 2012 (54) FATTY ACID-PHARMACEUTICAL AGENT (56) References Cited CONUGATES U.S. PATENT DOCUMENTS (75) Inventors: Nigel L. Webb, Bryn Mawr, PA (US); 3,539,573 A 11/1970 Schmutz Matthews O. Bradley, Laytonsville, 4,088.646 A * 5/1978 Ishida et al. .................. 544,313 4,097,597 A 6, 1978 Horrom et al. MD (US); Charles S. Swindell, Merion, 4,185,095 A 1/1980 Young PA (US); Victor E. Shashoua, 4,287.184 A 9/1981 Young Brookline, MA (US) 4,346,085 A 8, 1982 Growdon et al. 4,351,831 A 9, 1982 Growden et al. 4,407,744 A 10/1983 Young (73) Assignee: Luitpold Pharmaceuticals, Inc., 4.550,109 A 10, 1985 Folkers et al. Shirley, NY (US) 4,554,272 A 11/1985 Bocket al. 4,558,049 A 12/1985 Bernardi et al. 4,636,494. A 1/1987 Growdon et al. (*) Notice: Subject to any disclaimer, the term of this 4,684,646 A 8/1987 Chang et al. patent is extended or adjusted under 35 4,692,441 A 9, 1987 Alexander et al. U.S.C. 154(b) by 0 days. 4,704,393 A 1 1/1987 Wakabayashi et al. 4,729,989 A 3, 1988 Alexander This patent is Subject to a terminal dis 4,788,063 A 11/1988 Fisher et al. claimer. (Continued) (21) Appl. No.: 10/455.250 FOREIGN PATENT DOCUMENTS DE 2602175 7, 1976 (22) Filed: Jun. 5, 2003 (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2004/0106589 A1 Jun. 3, 2004 Hardman, J. G., Editor-in-Chief of Goodman & Gilman's The Phar macological Basis of Therapeutics, Ninth Edition, pp. 1225-1233 and Related U.S. Application Data 1243-1252, 1996.* (Continued) (63) Continuation of application No. 09/730,450, filed on Dec. 5, 2000, now Pat. No. 6,576,636, which is a Primary Examiner — Phyllis G. Spivack continuation of application No. 08/651,428, filed on (74) Attorney, Agent, or Firm — Wolf, Greenfield & Sacks, May 22, 1996, now abandoned. P.C. (57) ABSTRACT (51) Int. C. The invention provides conjugates offatty acids and pharma A6 IK3I/7068 (2006.01) ceutical agents useful in treating noncentral nervous system (52) U.S. Cl. ......................................................... S14/49 conditions. Methods for selectively targeting pharmaceutical (58) Field of Classification Search ........................ None agents to desired tissues are provided. See application file for complete search history. 6 Claims, 14 Drawing Sheets 5 O -5 OO - OO -9 -8 -7 -6 -5 -4 LOG-10 OF SAMPLE CONCENTRATION (MOLAR) CCRF-CEM-O- SR. ----- RPM-8226--e- - - K-562- - -a - - HL-60 (TB)-(- - MOLT-4 D . US 8,314,077 B2 Page 2 U.S. PATENT DOCUMENTS 6,043,230 A 3/2000 Arimilli et al. 4.814,470 A 3, 1989 Colin et all 6,069,249 A 5/2000 Arimilli et al. 4,857,653 A 8/1989 Colin et al. 88s. A 358 SAeneal 4,868,161 A 9/1989 Roberts 6.107,499 A 82000 Shashoua 4.902,505 A 2/1990 Pardridge et al. 6.136,796 A 10/2000 Kozak 4,933,324. A 6/1990 Shashoua 6,153,653 A 2000 Shashoua 4,939,174. A 7/1990 Shashoua 6.166,089 A 32000 Kozak 4,943,579 A 7, 1990 Vishnuvajala et al. 6.97,764 B1 3/2001 Bradley 4,968,672 A 11, 1990 Jacobson et al. 6,225.444 B1 5, 2001 Shashoua 5,059,699 A 10/1991 Kingston et al. 6,225.460 Bi 52001 Bischofberger etal 5,068.224. A 1 1/1991 Frvklund et al. 4- 4 - Derger et al. 5.2556 A 5, 1992 ME Camine 6,245,811 B1 6/2001 Horrobin et al. 5,112,863 A 5/1992 Hashimoto et al. 3. R $398: S. 5,116,624. A 5/1992 Horrobin et al. 6.28376 B 82001 Whittaker et al. 5, 120,760 A 6/1992 Horrobin 6.291,690 B1 9/2001 Mayhew et al. 5,141,958 A 8, 1992 Crozier-Willi et al. 6,384,019- w B1 5, 2002 Mvhynren ettal al. 5,169,762. A 12/1992 Grey et al. 6,407,075 B1 6/2002 Scott et al. 5,169,764 A 12/1992 Shooter et al. 6407135 B1 6/2002 Lai etal 5,194,654. A 3/1993 Hostetler et al. 6,448,392 B1 9/2002 Hostetler et al 5,214,062 A 5, 1993 Market al. I w 5,216.023. A 6/1993 Literatietal 6,576,636 B2 * 6/2003 Webb et al. .............. 514,263.38 4 kW - c. 6,602,902 B2 * 8/2003 Shashoua et al. ... 514,449 5,216,142 A 6, 1993 Horribinet al. T.235.583 B1 6, 2007 Webb etal 5,246,7265,223,263 A 9,6/1993 1993 HostetlerHorrobin et al. 7.816,398wkw B2: 10/2010 SwindeletalWindell et al. .............. 514,449 5,250,722 A 10/1993 Bombardelli et al. 2001/0006962 Al 72001 Myhren et al. 5,276,020 A 1/1994 Horribin et al. 2003/0065023 Al 42003 Swindellet al. 5,284.876 A 2, 1994 Shashoua 2012/0148595 A1 6, 2012 Swindell et al. 5,308,832 A 5/1994 Garleb et al. 5,314,991 A 5, 1994 Oka et al. FOREIGN PATENT DOCUMENTS 5,336,684. A 8/1994 Murray et al. DE 4224.737 2, 1994 5,352.596 A 10/1994 Cheung et al. EP 0 030 009 A1 6, 1981 5,356,928 A 10/1994 Murray et al. EP 0 091 694 A1 10, 1983 5.362,831 A 1 1/1994 Mongelli et al. EP O 311 100 A2 4, 1989 5,411,947 A 5/1995 Hostetler et al. EP O 350 287 10, 1990 5,420,276 A 5/1995 Norbeck EP O 599 576 A1 1/1994 5,447.936 A 9/1995 Hausheer et al. EP O 615 752 A2 9, 1994 5,453.520 A 9/1995 Bombardelli et al. EP O 693 498 A1 1, 1996 5,453.521. A 9/1995 Gaullier et al. FR 2698 269 A 8, 1997 5,459.256 A 10/1995 Marquez et al. JP T5-9469 1, 1975 5,466,841. A 1 1/1995 Horrobin et al. JP T5-427/1983 4f1983 5,468,754. A 1 1/1995 Hausheer et al. JP 59025327 A 2, 1984 5,473,055 A 12/1995 Mongelli et al. JP 59-2041.75 11, 1984 5,476,954. A 12/1995 Bourzat et al. JP 61204136 11, 1984 5,484.809 A 1/1996 Hostetler et al. JP 1153629. A 6, 1989 5,484.876 A 1/1996 Kawakami JP 1203331 A 8, 1989 5,494,999 A 2, 1996 Hale et al. JP 1287022. A 11, 1989 5,496,714. A 3/1996 Comb et al. JP 6O16548 A 1, 1994 5,504,102 A 4/1996 Agharkar et al. JP 6O72868 3, 1994 5,516,800 A 5/1996 Horrobin JP TO82146 3, 1995 5,532,372 A 7/1996 Saji et al. JP 8027010 A 1/1996 5,532,374. A 7/1996 Lee et al. JP 8151334 6, 1996 5.534499 A 7/1996 Ansell JP 8163991. A 6, 1996 5,545,719 A 8/1996 Shashoua JP 8245378 A 9, 1996 5,580,556 A 12/1996 Horrobin JP 9025231. A 1/1997 5,580,899 A 12/1996 Mayhew et al. JP 9030963 2, 1997 5,597.719 A 1/1997 Freed et al. WO WO 85,00520 2, 1985 5,603,959 A 2/1997 Horrobin et al. WO WO 89.02733 4f1989 5,604,198. A 2, 1997 Poduslo et al. WO WO 89,07938 9, 1989 5,604,216 A 2, 1997 Horrobin WO WO 90/OO555 1, 1990 5,646,180 A 7/1997 Chaturvedi WO WO92, 16554 10, 1992 5,654.290 A 8/1997 Bayon et al. WO WO92/2O362 11, 1992 5,716,614 A 2, 1998 Katz et al. WO WO93/OO910 1, 1993 5,750,572 A 5/1998 Bruzzese WO WO93, 11668 6, 1993 5,795,909 A 8/1998 Shashoua et al. WO WO94,07880 4f1994 5,814,456 A 9, 1998 O’Rand et al. WO WO94/11547 5, 1994 5,824,701 A 10/1998 Greenwald et al. WO WO 94.12530 6, 1994 5,827,819 A 10/1998 Yatvin et al. WO WO94f13654 6, 1994 5,919,815. A 7/1999 Bradley et al. WO WO94/20089 A1 9, 1994 5,922,695 A 7/1999 Arimilliet al. WO WO94,22887 10, 1994 5,925,669 A 7/1999 Katz et al. WO WO94,24107 10, 1994 5,955.459 A 9/1999 Bradley et al. WO WO95/O1969 1, 1995 5,977,061 A 1 1/1999 Holy et al. WO WO95/13270 5, 1995 5,977,089 A 1 1/1999 Arimilliet al. WO WO95/13271 5, 1995 5,977,174. A 1 1/1999 Bradley et al. WO WO95/33736 12/1995 5,985,854. A 1 1/1999 Kozak WO WO 96.01259 1, 1996 5,994,392 A 1 1/1999 Shashoua WO WO96,04001 2, 1996 6,005,004 A 12/1999 Katz et al. WO WO96, 12696 5, 1996 6,024,977 A 2/2000 Yatvin et al. WO WO96,22303 T 1996 US 8,314,077 B2 Page 3 WO WO96,27380 9, 1996 7-Phosphonooxymethyl Ether, a Potential Prodrug of Paclitaxel.” J.